Sources said that the biological E’s Corbevax along with Kovashield or Covaxin is likely to be considered by NTAGI as a booster for those fully vaccinated against COVID-19, which is due to meet on Tuesday. Is. The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precautionary dose for people aged 18 years and above. India’s first indigenously developed RBD protein subunit vaccine, Corbevax, is currently being used to vaccinate children in the age group of 12 to 14 years.
A source told PTI, “The National Technical Advisory Group on Immunization (NTAGI) will discuss allowing Corbevax, which has been approved by DCGI as a booster for those fully vaccinated with Kovashield or Covaxin. ” The government advisory panel is also expected to review trial data for the country’s first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer developed by the Serum Institute of India.
Sources had said that a separate HPV working group at NTAGI had on June 8 examined clinical trial data of the vaccine and its utility for inclusion in the national immunization programme. The NTAGI’s Standing Technical Sub-Committee (STSC)’s recommendation to reduce the gap between the second dose and the precautionary dose of COVID vaccines from nine to six months is also likely to be ratified in the meeting to be chaired by the Union Health Ministry. Secretary.
Read all the latest news, breaking news, watch top videos and watch Live TV right here.